Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muhammad Abdul-Ghani

Showing results (41-50 of 98) with videos related to

Pageof 10
Sort By:
Diabetes Care|June 23, 2017
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?Muhammad Abdul-Ghani, Ralph A DeFronzo, Stefano Del Prato, et al.
Diabetes Care|December 4, 2020
Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICTMuhammad Abdul-Ghani, Curtiss Puckett, John Adams, et al.
Diabetes Care|January 19, 2017
Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar StudyMuhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, et al.
The Journal of Clinical Endocrinology and Metabolism|June 12, 2020
Pitfalls of HbA1c in the Diagnosis of DiabetesMichael Bergman, Muhammad Abdul-Ghani, João Sérgio Neves, et al.
BMJ Open Diabetes Research & Care|April 27, 2025
Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT studyMuhammad Abdul-Ghani, Curtiss Puckett, Siham Abdelgani, et al.
Plos One|December 12, 2019
Predicting long-term type 2 diabetes with support vector machine using oral glucose tolerance testHasan T Abbas, Lejla Alic, Madhav Erraguntla, et al.
Diabetes Care|March 30, 2020
Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA<sub>1c</sub>, in Patients With Type 2 DiabetesAli Muhammed Ali, Robert Martinez, Hussein Al-Jobori, et al.
Diabetes|April 22, 2017
Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 DiabetesHussein Al-Jobori, Giuseppe Daniele, Eugenio Cersosimo, et al.
Diabetes|October 9, 2020
Effect of Mild Physiologic Hyperglycemia on Insulin Secretion, Insulin Clearance, and Insulin Sensitivity in Healthy Glucose-Tolerant SubjectsAurora Merovci, Devjit Tripathy, Xi Chen, et al.
The Journal of Clinical Endocrinology and Metabolism|January 15, 2016
Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM MalesAurora Merovci, Muhammad Abdul-Ghani, Andrea Mari, et al.
Pageof 10

Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
Diabetes Care|June 23, 2017
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?Muhammad Abdul-Ghani, Ralph A DeFronzo, Stefano Del Prato, et al.
Diabetes Care|December 4, 2020
Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICTMuhammad Abdul-Ghani, Curtiss Puckett, John Adams, et al.
Diabetes Care|January 19, 2017
Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar StudyMuhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, et al.
The Journal of Clinical Endocrinology and Metabolism|June 12, 2020
Pitfalls of HbA1c in the Diagnosis of DiabetesMichael Bergman, Muhammad Abdul-Ghani, João Sérgio Neves, et al.
BMJ Open Diabetes Research & Care|April 27, 2025
Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT studyMuhammad Abdul-Ghani, Curtiss Puckett, Siham Abdelgani, et al.
Plos One|December 12, 2019
Predicting long-term type 2 diabetes with support vector machine using oral glucose tolerance testHasan T Abbas, Lejla Alic, Madhav Erraguntla, et al.
Diabetes Care|March 30, 2020
Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA<sub>1c</sub>, in Patients With Type 2 DiabetesAli Muhammed Ali, Robert Martinez, Hussein Al-Jobori, et al.
Diabetes|April 22, 2017
Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 DiabetesHussein Al-Jobori, Giuseppe Daniele, Eugenio Cersosimo, et al.
Diabetes|October 9, 2020
Effect of Mild Physiologic Hyperglycemia on Insulin Secretion, Insulin Clearance, and Insulin Sensitivity in Healthy Glucose-Tolerant SubjectsAurora Merovci, Devjit Tripathy, Xi Chen, et al.
The Journal of Clinical Endocrinology and Metabolism|January 15, 2016
Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM MalesAurora Merovci, Muhammad Abdul-Ghani, Andrea Mari, et al.
Pageof 10